Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation

Siponimod (Mayzent(®)), a sphingosine 1-phosphate receptor (S1PR) modulator which prevents lymphocyte egress from lymphoid tissues, is approved for the treatment of relapsing-remitting and active secondary progressive multiple sclerosis. It can cross the blood–brain barrier (BBB) and selectively bin...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruchot, Joel, Lein, Ferdinand, Lewen, Isabel, Reiche, Laura, Weyers, Vivien, Petzsch, Patrick, Göttle, Peter, Köhrer, Karl, Hartung, Hans-Peter, Küry, Patrick, Kremer, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655930/
https://www.ncbi.nlm.nih.gov/pubmed/36362063
http://dx.doi.org/10.3390/ijms232113278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655930/
https://www.ncbi.nlm.nih.gov/pubmed/36362063
http://dx.doi.org/10.3390/ijms232113278

Ejemplares similares